Loading...
Docoh

Zoetis (ZTS)

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.

Company profile

Ticker
ZTS
Exchange
Website
CEO
Kristin Peck
Employees
Location
Fiscal year end
SEC CIK
Subsidiaries
Abaxis Asia Limited • Abaxis Europe GmbH • Abaxis South East Europe • Abaxis UK Limited • Abaxis, Inc. • Alpharma (Bermuda), LLC • Alpharma (Luxembourg) S.A.R.L. • Alpharma Animal Health (Hong Kong) Co. Limited • Alpharma Animal Health Company • Alpharma do Brasil Ltda. ...
IRS number
460696167

ZTS stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$203.50
Low target
$202.00
High target
$205.00
Goldman Sachs
Maintains
Buy
$202.00
21 Jul 22
Piper Sandler
Initiated
Overweight
$205.00
12 Jul 22

Calendar

4 Aug 22
28 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 2.65B 2.65B 2.65B 2.65B 2.65B 2.65B
Cash burn (monthly) 161M 83.83M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 475.44M 247.57M n/a n/a n/a n/a
Cash remaining 2.18B 2.4B n/a n/a n/a n/a
Runway (months of cash) 13.5 28.7 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Aug 22 Robert J Polzer Common Stock Sell Dispose S No No 171.7701 1,120 192.38K 1,937
5 Aug 22 Robert J Polzer Common Stock Option exercise Acquire M No No 87.51 1,721 150.6K 3,057
5 Aug 22 Robert J Polzer Stock Option Common Stock Option exercise Dispose M No No 0 1,721 0 7,691
25 Jul 22 Vanessa Broadhurst RSU Common Stock Grant Acquire A No No 0 1,370 0 1,370
22 Jul 22 Lagano Roxanne Common Stock Sell Dispose S No No 180.26 2,167 390.62K 23,687
22 Jul 22 Lagano Roxanne Common Stock Option exercise Acquire M No No 87.51 1,004 87.86K 25,854
22 Jul 22 Lagano Roxanne Common Stock Option exercise Acquire M No Yes 73.24 1,163 85.18K 24,850
22 Jul 22 Lagano Roxanne Stock Option Common Stock Option exercise Dispose M No No 0 1,004 0 37,569
22 Jul 22 Lagano Roxanne Stock Option Common Stock Option exercise Dispose M No No 0 1,163 0 38,573
21 Jul 22 Peck Kristin C Common Stock Sell Dispose S No No 180 9,689 1.74M 39,743
89.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1477 1547 -4.5%
Opened positions 108 141 -23.4%
Closed positions 178 179 -0.6%
Increased positions 545 578 -5.7%
Reduced positions 612 606 +1.0%
13F shares Current Prev Q Change
Total value 72.22B 79.79B -9.5%
Total shares 419.53M 423.15M -0.9%
Total puts 772.38K 1.07M -28.1%
Total calls 1.92M 1.94M -0.8%
Total put/call ratio 0.4 0.6 -27.5%
Largest owners Shares Value Change
BLK Blackrock 43.46M $7.47B +4.1%
Vanguard 36.24M $6.23B +0.9%
STT State Street 19.72M $3.39B +0.1%
Alliancebernstein 18.69M $3.21B +1.7%
State Farm Mutual Automobile Insurance 17.13M $2.95B 0.0%
FMR 12.56M $2.16B -5.2%
BAC Bank Of America 11.9M $2.05B -6.8%
TROW T. Rowe Price 10.01M $1.72B +5.3%
Geode Capital Management 9.45M $1.62B +3.3%
Capital World Investors 8.96M $1.54B -0.4%
Largest transactions Shares Bought/sold Change
Sands Capital Management 611.49K -2.34M -79.3%
Parametric Portfolio Associates 0 -2.01M EXIT
Capital International Investors 7.17M +1.86M +35.0%
BLK Blackrock 43.46M +1.69M +4.1%
MS Morgan Stanley 7.68M +1.6M +26.3%
Arrowstreet Capital, Limited Partnership 2.09M -1.24M -37.3%
Wellington Management 7.51M +1.21M +19.1%
Winslow Capital Management 3.04M +1.14M +59.6%
NN Investment Partners 0 -898.94K EXIT
MNGPF Man 0 -889.89K EXIT

Financial report summary

?
Risks
  • Our business is subject to risk based on global economic and political conditions.
Management Discussion
  • Total revenue increased by $104 million, or 5%, in the three months ended June 30, 2022, compared with the three months ended June 30, 2021, an increase of $161 million, or 8%, on an operational basis. Operational revenue growth was comprised primarily of the following:
  • •volume decrease from other in-line products of approximately 3%.
  • Foreign exchange decreased reported revenue growth by approximately 3%.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: American, Apoquel, Argentina, Argentine, Certificate, Cytopoint, exceeded, exceptionally, inflationary, Latin, lease, Norway, petcare, rotational, surpassed, Venezuela, war, Zealand
Removed: Alpha, Flux, lice, platform, sea, vaccine, vendor